3647 results for «604»

Filter By

3647 results

TAVI and alternative access

19 Feb 2023 – From PCR Tokyo Valves 2023

Learn more about TAVI in this session by reviewing case submissions on topics such as bailout transseptal approach, primary percutaneous transaxillary TAVI, and transapical TAVI with chimney stenting. 

Imaging for structural heart disease intervention

19 Feb 2023 – From PCR Tokyo Valves 2023

Consult this session if you want to learn about imaging in structural heart interventions by exploring series of slides on restoration post transcatheter mitral valve repair, diagnostic performance of CT angiography, and AI in aortic complex measurement for TAVI, and more! 

Complex CTO challenges

22 Sep 2023 – From AICT-AsiaPCR 2023

Gain valuable insights into overcoming CTO challenges in this session: learn how IVUS can come to the rescue in cases of main branch cut-off, discover successful recanalization techniques for right coronary artery CTOs using very long epicardial channels and explore the best approaches for managing complex...

Complex CTO challenges

Complication and bailout of TAVI

18 Feb 2023 – From PCR Tokyo Valves 2023

As TAVI is never risk-free, learn about bailout techniques to counter various complications. This session explores cases such as failure to release aortic stenosis after implantation of a self-expanding valve, retrieving a pigtail catheter straightener dropped into aorta and balloon rupture during TAVI.

Which AF patients may benefit from LAA closure?

02 Jul 2026

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Martin W. Bergmann

Author

Martin W. Bergmann
Which AF patients may benefit from LAA Closure?

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

Future directions of drug-coated balloon angioplasty

06 Feb 2025

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Dr. F. Alfonso

Author

Fernando Alfonso
Javier Cuesta

Author

Javier Cuesta
Future directions of drug-coated balloon angioplasty
Didn’t find what you were looking for?